Henry Gosebruch, Neumora Therapeutics CEO
January 2, 2025 07:25 AM ESTUpdated 10:02 AM
R&D

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Kyle LaHucik

Senior Reporter

Neu­ro­science drug de­vel­op­er Neumo­ra Ther­a­peu­tics re­leased high­ly an­tic­i­pat­ed re­sults from the first of three Phase 3 tri­als for its ex­per­i­men­tal ma­jor …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A look at biotech's year of the megaround

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Flag­ship biotech Va­lo Health ends 2024 with mid-stage fail

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times